COMMUNIQUÉS West-GlobeNewswire

Suja Life to Report First Quarter 2026 Financial Results on June 9, 2026
19/05/2026
OCEANSIDE, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- Suja Life, Inc. (NASDAQ: SUJA) (“Suja Life” or the “Company”), a leading better-for-you beverage company and maker of Suja Organic , Vive Organic , and Slice Soda , [...]
Ipsen annonce des données « late-breaking » issues de la première étude comparative directe entre Dysport® et Botox® chez des adultes atteints de spasticité du membre supérieur
19/05/2026
Essai de phase IV comparatif direct, en double aveugle, évaluant la tolérance et l’efficacité ayant atteint ses critères principaux et secondaires Les résultats de l’étude DIRECTION montrent que le profil de sécurité de [...]
Ipsen announces late-breaking data from first head-to-head study comparing Dysport® and Botox® in adults with upper limb spasticity
19/05/2026
Phase IV head-to-head, double-blind trial comparing safety and efficacy met its primary and secondary endpoints The DIRECTION trial results show the safety profile for Dysport ® (abobotulinumtoxinA) was non-inferior to [...]
Solésence Day Mode Hero Concealer SPF 50+ Wins Three Categories at the 2026 Cosmetics & Toiletries Allē Awards, Marking Fourth Year of Recognition
19/05/2026
SPF-Infused Concealer Featuring Kleair™ , WHSPR™ , and Chromalüm™ Recognized Across Anti-Aging, Color Cosmetics, and Compromised Skin ROMEOVILLE, Ill., May 19, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc . (Nasdaq: SLSN) a [...]
Vaxart Files Preliminary Proxy Statement and Issues Open Letter to Shareholders
19/05/2026
Company is Entering a Pivotal Phase to Demonstrate Value of its Unique Oral Vaccine Platform Emphasizes Need for the Right Board Leadership at Critical Strategic Juncture Encourages Shareholders to Visit Vote.Vaxart.com [...]
Relay Therapeutics Announces Proposed Public Offering of Common Stock
19/05/2026
CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living [...]
NurExone Receives Notice of Patent Grant in South Korea Covering ExoPTEN Technology
19/05/2026
Expands intellectual property protection in a strategically important market for the Company’s lead exosome-based therapy targeting nerve repair and functional recovery TORONTO, Ontario and HAIFA, Israel, May 19, 2026 ( [...]
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases
19/05/2026
Late-breaking oral presentation to highlight AlloNK + rituximab clinical responses comparable to autologous CAR T-cell therapy in 31 patients with rheumatologic diseases, including 71% ACR50 response in refractory [...]
Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit
19/05/2026
SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA) today announced its participation in the TD Cowen 7 th Annual Oncology Innovation Summit: Insights for ASCO & EHA. Kura management is [...]
Radiology Associates of North Texas Announces Analysis Projecting More than $51 Million in No Surprises Act Administrative Costs
19/05/2026
Nation’s largest radiology practice reveals BCBS TX has paid just 2% of binding federal arbitration awards, leaving millions in limbo following recent 5th Circuit ruling Fort Worth, TX, May 19, 2026 (GLOBE NEWSWIRE) -- [...]
Oorja Bio Unveils Clinical Data for ORJ-001, a First-in-Class Therapeutic Targeting Alveolar Epithelial Type 2 (AEC2) Cells for Treatment of Idiopathic Pulmonary Fibrosis (IPF)
19/05/2026
ORJ-001 achieved therapeutic exposure and was well tolerated in Phase 1 study, supporting company’s plans to initiate Phase 2 clinical trial in IPF patients Data from preclinical studies of ORJ-001 demonstrated durable [...]
Oorja Bio Launches as a Clinical-Stage Company to Develop Groundbreaking Therapies for Idiopathic Pulmonary Fibrosis (IPF) and Other Fibrotic Diseases
19/05/2026
Company announces $30 million Series A financing and founding leadership team with expertise in pulmonary drug innovation and track record advancing novel therapies to patients ORJ-001, set to begin a Phase 2 clinical [...]
Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment
19/05/2026
ORCA-OL data complete the clinical evidence package supporting the cytisinicline smoking cessation NDA No new safety signals identified by the independent Data Safety Monitoring Committee over 52 weeks of continuous [...]
Comfort Keepers Ireland Highlights Urgent Need for Dementia Care as Cases Set to Double by 2045
19/05/2026
Report Reveals 64,000 People Currently Living with Dementia in Ireland, Emphasizing Home-Based Support Dublin, IRELAND, May 19, 2026 (GLOBE NEWSWIRE) -- A new industry report from Comfort Keepers Ireland has underscored [...]
BC-led clinical trial points to safer care for critically ill patients
19/05/2026
Royal Columbian Hospital and Simon Fraser University researchers report reduction in central-line complications in JAMA-published Canadian ICU study NEW WESTMINSTER, British Columbia, May 19, 2026 (GLOBE NEWSWIRE) -- A [...]
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Avril 2026
19/05/2026
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers Sanofi Société [...]
Sanofi: Information concerning the total number of voting rights and shares - April 2026
19/05/2026
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’ [...]
IBA – ACQUISITION D’ACTIONS PROPRES
19/05/2026
Louvain-la-Neuve, Belgique, 19 mai 2026 – 18h00 – Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") communique [...]
Altitude Lab Portfolio Companies Surpass $205 Million in Funding, Marking a New Era for Early-Stage Biotechs in Salt Lake City
19/05/2026
SALT LAKE CITY, May 19, 2026 (GLOBE NEWSWIRE) -- Altitude Lab , the platform-first biotech-startup accelerator founded by Recursion (NASDAQ: RXRX), announced today that its portfolio companies have collectively raised [...]

Pages